Hidetomo Murakami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hidetomo Murakami has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Mitsuru Kawamura
9 shared publications- Kenjiro Ono
Department of Neurology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
5 shared publications Hidetaka Mitsumura
Department of Neurology, School of Medicine, The Jikei University, Tokyo, Japan
4 shared publicationsTakahiro Maku
Department of Neurology, School of Medicine, The Jikei University, Tokyo, Japan
4 shared publicationsHiroki Takatsu
Department of Neurology, School of Medicine, The Jikei University, Tokyo, Japan
3 shared publicationsKenichiro Sakai
Department of Neurology, School of Medicine, The Jikei University, Tokyo, Japan
3 shared publications
Latest Publications
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S7)
Myricetin prevents high molecular weight Aβ1‐42 oligomer‐induced neurotoxicity through antioxidant effects in cell membranes and mitochondria
Background: Excessive accumulation of amyloid β‐protein (Aβ) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of Alzheimer’s disease (AD). Protofibrils, one of the high‐molecular‐weight Aβ oligomers (HMW‐Aβo), are implicated to be important targets of disease modifying therapy of AD.We previously reported that phenolic compounds such as myricetin inhibit Aβ1‐40, Aβ1‐42, and α‐synuclein aggregations, including their oligomerizations, which may exert protective effects against AD and Parkinson’s disease. The purpose of this study was to clarify the detailed mechanism of the protective effect of myricetin against the neurotoxicity of HMW‐Aβo in SH‐SY5Y cells.Method: To assess the effect of myricetin on HMW‐Aβo‐induced oxidative stress, we systematically examined the level of membrane oxidative damage by measuring cell membrane lipid peroxidation, membrane fluidity, and cell membrane potential, and the mitochondrial oxidative damage was evaluated by mitochondrial permeability transition (MPT), mitochondrial reactive oxygen species (ROS), and manganese‐superoxide dismutase (Mn‐SOD), and adenosine triphosphate (ATP) assay in SH‐SY5Y cells.Result: Myricetin has been found to increased cell viability by suppression of HMW‐Aβo‐induced membrane disruption in SH‐SY5Y cells, as shown in reducing membrane phospholipid peroxidation and increasing membrane fluidity and membrane resistance. Myricetin has also been found to suppress HMW‐Aβo‐induced mitochondria dysfunction, as demonstrated in decreasing MPT, Mn‐SOD, and ATP generation, raising mitochondrial membrane potential, and increasing mitochondrial‐ROS generation.Conclusion: These results suggest that myricetin preventing HMW‐Aβo‐induced neurotoxicity through multiple antioxidant functions may be developed as a disease‐modifying agent against AD.
- 16 June 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S7)
Myricetin prevents high molecular weight Aβ1‐42 oligomer‐induced neurotoxicity through antioxidant effects in cell membranes and mitochondria
Background: Excessive accumulation of amyloid β‐protein (Aβ) is one of the primary mechanisms that leads to neuronal death with phosphorylated tau in the pathogenesis of Alzheimer’s disease (AD). Protofibrils, one of the high‐molecular‐weight Aβ oligomers (HMW‐Aβo), are implicated to be important targets of disease modifying therapy of AD.We previously reported that phenolic compounds such as myricetin inhibit Aβ1‐40, Aβ1‐42, and α‐synuclein aggregations, including their oligomerizations, which may exert protective effects against AD and Parkinson’s disease. The purpose of this study was to clarify the detailed mechanism of the protective effect of myricetin against the neurotoxicity of HMW‐Aβo in SH‐SY5Y cells.Method: To assess the effect of myricetin on HMW‐Aβo‐induced oxidative stress, we systematically examined the level of membrane oxidative damage by measuring cell membrane lipid peroxidation, membrane fluidity, and cell membrane potential, and the mitochondrial oxidative damage was evaluated by mitochondrial permeability transition (MPT), mitochondrial reactive oxygen species (ROS), and manganese‐superoxide dismutase (Mn‐SOD), and adenosine triphosphate (ATP) assay in SH‐SY5Y cells.Result: Myricetin has been found to increased cell viability by suppression of HMW‐Aβo‐induced membrane disruption in SH‐SY5Y cells, as shown in reducing membrane phospholipid peroxidation and increasing membrane fluidity and membrane resistance. Myricetin has also been found to suppress HMW‐Aβo‐induced mitochondria dysfunction, as demonstrated in decreasing MPT, Mn‐SOD, and ATP generation, raising mitochondrial membrane potential, and increasing mitochondrial‐ROS generation.Conclusion: These results suggest that myricetin preventing HMW‐Aβo‐induced neurotoxicity through multiple antioxidant functions may be developed as a disease‐modifying agent against AD.
- 15 November 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (3) , 913-918
Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson’s disease are dependent on frontal function
Background Monotherapy with monoamine oxidase B (MAO-B) inhibitors enhances the level of endogenous dopamine in treatment for Parkinson’s disease (PD) and provides some benefits. Certain neuropsychiatric functions are also regulated by central dopaminergic activity. Aim To investigate the relationship of the efficacy of monotherapy with MAO-B inhibitors on motor symptoms in PD with baseline cognitive function. Patients and methods Outcomes were examined for 27 consecutive drug-naïve PD patients who received initial treatment with a MAO-B inhibitor (selegiline: 11, rasagiline: 16). Selegiline was titrated to an optimal dose. The dose of rasagiline was fixed at 1 mg/day. Motor symptoms were assessed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III before treatment and after the efficacy reached a plateau within 19 weeks after drug initiation, and the % improvement in motor symptoms was calculated. Pre-treatment cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery (FAB). Correlations of % improvement in motor symptoms and baseline cognitive assessments were examined using Spearman correlation coefficients and multiple regression analysis. Results In all patients, the mean % improvement in motor symptoms was 46.5% (range 0–83.3%). Spearman correlation coefficients showed the % improvement in motor symptoms was correlated with FAB (r = 0.631, p < 0.001). In multiple regression analysis with patient background factors as independent variables, only FAB was associated with improvement in motor symptoms in the MAO-B group. Conclusion Better FAB scores predict a significant improvement in motor symptoms with treatment with MAO-B inhibitors, suggesting high activity of endogenous dopamine.
- 15 November 2022
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (3) , 913-918
Effects of monotherapy with a monoamine oxidase B inhibitor on motor symptoms in Parkinson’s disease are dependent on frontal function
Background Monotherapy with monoamine oxidase B (MAO-B) inhibitors enhances the level of endogenous dopamine in treatment for Parkinson’s disease (PD) and provides some benefits. Certain neuropsychiatric functions are also regulated by central dopaminergic activity. Aim To investigate the relationship of the efficacy of monotherapy with MAO-B inhibitors on motor symptoms in PD with baseline cognitive function. Patients and methods Outcomes were examined for 27 consecutive drug-naïve PD patients who received initial treatment with a MAO-B inhibitor (selegiline: 11, rasagiline: 16). Selegiline was titrated to an optimal dose. The dose of rasagiline was fixed at 1 mg/day. Motor symptoms were assessed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III before treatment and after the efficacy reached a plateau within 19 weeks after drug initiation, and the % improvement in motor symptoms was calculated. Pre-treatment cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) and Frontal Assessment Battery (FAB). Correlations of % improvement in motor symptoms and baseline cognitive assessments were examined using Spearman correlation coefficients and multiple regression analysis. Results In all patients, the mean % improvement in motor symptoms was 46.5% (range 0–83.3%). Spearman correlation coefficients showed the % improvement in motor symptoms was correlated with FAB (r = 0.631, p < 0.001). In multiple regression analysis with patient background factors as independent variables, only FAB was associated with improvement in motor symptoms in the MAO-B group. Conclusion Better FAB scores predict a significant improvement in motor symptoms with treatment with MAO-B inhibitors, suggesting high activity of endogenous dopamine.
- 7 July 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (12) , 6658-6660
Repeated erythema and pain in the lateral thoracic region due to spinal cord infarction: a case report
- 7 July 2022
- Published by Springer Nature in Journal of Neurology
- Vol. 269 (12) , 6658-6660
Repeated erythema and pain in the lateral thoracic region due to spinal cord infarction: a case report
- Open Access
- 1 January 2022
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 62 (5) , 380-385
A 73-year-old man with polyradiculopathy and multiple cranial neuropathies emerging separate from the originating dermatome of a varicella zoster skin lesion
症例は73歳男性.左頸部C3~4皮膚分節に帯状疱疹を発症し皮疹は痂皮化したが,その翌日から同側第V,VII,VIII脳神経障害と同側C4~Th1髄節支配筋の脱力が出現した.アシクロビルの静注,ステロイドパルス療法,プレドニゾロンの内服治療後に全症状は消失した.当症例では皮疹を認めた皮膚分節より広範囲な神経障害を認めた点が特徴的であった.その機序として,脳脊髄液を介した波及,同時多発的な無疹性帯状疱疹,上位頸髄神経と脳神経の神経交通枝を介した経神経的な炎症波及が想定された.帯状疱疹の神経障害の多様性は髄膜炎,無疹性帯状疱疹の証明の困難さ,神経交通枝の存在の個体差に起因している可能性がある.
- 1 January 2022
- Published by Societas Neurologica Japonica in Rinsho Shinkeigaku
- Vol. 62 (5) , 380-385
Open AccessA 73-year-old man with polyradiculopathy and multiple cranial neuropathies emerging separate from the originating dermatome of a varicella zoster skin lesion
症例は73歳男性.左頸部C3~4皮膚分節に帯状疱疹を発症し皮疹は痂皮化したが,その翌日から同側第V,VII,VIII脳神経障害と同側C4~Th1髄節支配筋の脱力が出現した.アシクロビルの静注,ステロイドパルス療法,プレドニゾロンの内服治療後に全症状は消失した.当症例では皮疹を認めた皮膚分節より広範囲な神経障害を認めた点が特徴的であった.その機序として,脳脊髄液を介した波及,同時多発的な無疹性帯状疱疹,上位頸髄神経と脳神経の神経交通枝を介した経神経的な炎症波及が想定された.帯状疱疹の神経障害の多様性は髄膜炎,無疹性帯状疱疹の証明の困難さ,神経交通枝の存在の個体差に起因している可能性がある.
- 1 October 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (10) , 106049
Crossed Choreoathetosis Caused by Unilateral Thalamic Hemorrhage
- 1 October 2021
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 30 (10) , 106049
Crossed Choreoathetosis Caused by Unilateral Thalamic Hemorrhage
- 22 April 2021
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (12) , 5327-5334
Face pareidolia is associated with right striatal dysfunction in drug-naïve patients with Parkinson’s disease
Background and aim Some patients with Parkinson’s disease (PD) present with pareidolia, an illusion of a meaningless stimulus as a familiar object known to the observer. Since the striatum is associated with processing of visual information, we investigated correlations of pareidolia with motor symptoms and striatal dopaminergic function. Method A noise pareidolia test, assessment of motor symptoms using MDS-UPDRS and 123I-Ioflupane SPECT were performed in 58 drug-naïve PD patients. A number of images in which a participant noticed an illusory face (number of illusory responses) were compared with motor assessment scores and uptake of 123I-ioflupane in the striatum. Results Of the 58 participants, 22 had at least one illusory response. Mean scores for MDS-UPDRS part III (ppp123I-ioflupane in the right caudate nucleus (pppr=0.443, pr=0.440, pr=0.564, pp<0.05 by chi-square test). Conclusion Pareidolia in PD patients is associated with dysfunction in the right striatum.
- 22 April 2021
- Published by Springer Nature in Neurological Sciences
- Vol. 42 (12) , 5327-5334
Face pareidolia is associated with right striatal dysfunction in drug-naïve patients with Parkinson’s disease
Background and aim Some patients with Parkinson’s disease (PD) present with pareidolia, an illusion of a meaningless stimulus as a familiar object known to the observer. Since the striatum is associated with processing of visual information, we investigated correlations of pareidolia with motor symptoms and striatal dopaminergic function. Method A noise pareidolia test, assessment of motor symptoms using MDS-UPDRS and 123I-Ioflupane SPECT were performed in 58 drug-naïve PD patients. A number of images in which a participant noticed an illusory face (number of illusory responses) were compared with motor assessment scores and uptake of 123I-ioflupane in the striatum. Results Of the 58 participants, 22 had at least one illusory response. Mean scores for MDS-UPDRS part III (ppp123I-ioflupane in the right caudate nucleus (pppr=0.443, pr=0.440, pr=0.564, pp<0.05 by chi-square test). Conclusion Pareidolia in PD patients is associated with dysfunction in the right striatum.
- 19 April 2020
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (10) , 2825-2830
Differences in correlations of depression and anhedonia with cardiovascular sympathetic functions during a head-up tilt test in drug-naïve Parkinson’s disease patients
Background Depression is a symptom of Parkinson’s disease (PD) and may be correlated with cardiovascular sympathetic function. Anhedonia is an element of depression, but these symptoms can emerge independently in PD. A correlation of anhedonia with cardiovascular sympathetic function has rarely been examined. Objective To compare correlations of depression and anhedonia with cardiovascular sympathetic function in drug-naive PD patients. Methods Assessments of depression (Self-rating Depression Scale; SDS), anhedonia (Snaith–Hamilton Pleasure Scale; SHAPS), myocardial 123I-MIBG (123I-meta-iodobenzylguanidine) scintigraphy (heart to mediastinum (H/M) ratios in early and delayed images), and head-up tilt test (HUT) up to 60° for 10 min were performed in 45 drug-naïve PD patients. During the HUT, blood pressure was measured every minute and the maximum decrease in systolic blood pressure (SBP) was determined. Plasma noradrenaline (NA) and arginine vasopressin (AVP) levels were examined at baseline and 10 min after tilt, with subsequent calculation of increases in plasma NA and AVP levels in this 10 min. Correlation coefficients were calculated among these assessment parameters. Results SDS significantly correlated with % maximum decrease in SBP (r = 0.344, p = 0.02), but not with H/M ratios in both images and increases in plasma NA and AVP levels. SHAPS did not correlate with the change in SBP, H/M ratios in both images, or plasma NA and AVP levels. Conclusion Depression was correlated with the % maximum decrease in SBP during a 10-min HUT, but anhedonia did not show this relationship. This suggests that depression and anhedonia may have different pathophysiological backgrounds in drug-naïve PD patients.
- 19 April 2020
- Published by Springer Nature in Neurological Sciences
- Vol. 41 (10) , 2825-2830
Differences in correlations of depression and anhedonia with cardiovascular sympathetic functions during a head-up tilt test in drug-naïve Parkinson’s disease patients
Background Depression is a symptom of Parkinson’s disease (PD) and may be correlated with cardiovascular sympathetic function. Anhedonia is an element of depression, but these symptoms can emerge independently in PD. A correlation of anhedonia with cardiovascular sympathetic function has rarely been examined. Objective To compare correlations of depression and anhedonia with cardiovascular sympathetic function in drug-naive PD patients. Methods Assessments of depression (Self-rating Depression Scale; SDS), anhedonia (Snaith–Hamilton Pleasure Scale; SHAPS), myocardial 123I-MIBG (123I-meta-iodobenzylguanidine) scintigraphy (heart to mediastinum (H/M) ratios in early and delayed images), and head-up tilt test (HUT) up to 60° for 10 min were performed in 45 drug-naïve PD patients. During the HUT, blood pressure was measured every minute and the maximum decrease in systolic blood pressure (SBP) was determined. Plasma noradrenaline (NA) and arginine vasopressin (AVP) levels were examined at baseline and 10 min after tilt, with subsequent calculation of increases in plasma NA and AVP levels in this 10 min. Correlation coefficients were calculated among these assessment parameters. Results SDS significantly correlated with % maximum decrease in SBP (r = 0.344, p = 0.02), but not with H/M ratios in both images and increases in plasma NA and AVP levels. SHAPS did not correlate with the change in SBP, H/M ratios in both images, or plasma NA and AVP levels. Conclusion Depression was correlated with the % maximum decrease in SBP during a 10-min HUT, but anhedonia did not show this relationship. This suggests that depression and anhedonia may have different pathophysiological backgrounds in drug-naïve PD patients.
- Open Access
- 1 November 2018
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 14, 3185-3192
The subjective perception of past, present, and future time in patients with Alzheimer's disease: a qualitative study
Background: The relationship between dementia and time perception impairment is unknown. Aim: This study aims to explore subjective perception of the passage of time in patients with Alzheimer’s disease (AD). Methods: We conducted semi-structured interviews with 11 AD patients. Grounded theory, a qualitative research methodology, was used for data analysis. Results: Based on interview transcripts, five categories were designated: {Live according to a private clock}, {The past comes up}, {Move back and forth between the present and the past}, {Cannot imagine the future}, and {Bid farewell to this world as early as tomorrow}. Discussion: Our results suggest that AD patients alternate past and present without complete awareness and cannot imagine a future other than one ending in death.
- 1 November 2018
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 14, 3185-3192
Open AccessThe subjective perception of past, present, and future time in patients with Alzheimer's disease: a qualitative study
Background: The relationship between dementia and time perception impairment is unknown. Aim: This study aims to explore subjective perception of the passage of time in patients with Alzheimer’s disease (AD). Methods: We conducted semi-structured interviews with 11 AD patients. Grounded theory, a qualitative research methodology, was used for data analysis. Results: Based on interview transcripts, five categories were designated: {Live according to a private clock}, {The past comes up}, {Move back and forth between the present and the past}, {Cannot imagine the future}, and {Bid farewell to this world as early as tomorrow}. Discussion: Our results suggest that AD patients alternate past and present without complete awareness and cannot imagine a future other than one ending in death.
- Open Access
- 1 October 2017
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 13, 2719-2726
Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in patients with Parkinson’s disease (PD) are inconsistent. Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). Methods: PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems. All participants were tested prior to and at 4–7 months after the drug initiation/adjustment. Executive function was assessed by using the Behavioral Assessment of the Dysexecutive Syndrome (BADS). Motor function was assessed by using the Unified Parkinson’s Disease Rating Scale (UPDRS; part III). Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions. Results: The mean standardized BADS scores showed no significant improvement in both the groups. In the de novo group, percent improvement in the standardized BADS scores showed a significant positive correlation with the LED, but not with percent improvement in UPDRS part III. In the chronic medication group, percent improvement in the standardized BADS scores was negatively correlated with change in the LED, but not with percent improvement in UPDRS part III. Multiple regression analysis using improvement in the standardized BADS score as a dependent variable and patient’s background factors (ie, age, education, disease duration, and motor and executive assessments at baseline) as independent variable showed that improvement in the executive assessment is significantly correlated with the LED only in the de novo group. Conclusion: Effects of dopaminergic drug adjustment on executive function differ according to the patient’s clinical stage and depend on LED in de novo stage. Keywords: motor disorders, dopaminergic drug, levodopa equivalent dose, correlation between executive improvement and levodopa equivalent dose, inverted U-shaped theory
- 1 October 2017
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 13, 2719-2726
Open AccessEffects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson’s disease
Effects of dopaminergic drug adjustment on executive function in different clinical stages of Parkinson's disease Hidetomo Murakami, Tetsuhito Nohara, Hidenobu Shozawa, Yoshiyuki Owan, Takeshi Kuroda, Satoshi Yano, Machiko Kezuka, Mitsuru Kawamura, Kenjiro Ono Department of Neurology, School of Medicine, Showa University, Tokyo, Japan Background: Effects of dopaminergic medication on executive function in patients with Parkinson’s disease (PD) are inconsistent. Objective: We examined the effect of dopaminergic medication on executive function in 24 drug-naïve PD patients (de novo group) and in 21 PD patients on chronic dopaminergic medication (chronic medication group). Methods: PD patients without dementia were included in this study. For the de novo group patients, dopaminergic medication was initiated, and the dose was increased to improve motor symptoms. For the chronic medication group patients, dopaminergic medication was adjusted to relieve clinical problems. All participants were tested prior to and at 4–7 months after the drug initiation/adjustment. Executive function was assessed by using the Behavioral Assessment of the Dysexecutive Syndrome (BADS). Motor function was assessed by using the Unified Parkinson’s Disease Rating Scale (UPDRS; part III). Improvement in executive function was compared with a simultaneous change in levodopa equivalent doses (LED) of dopaminergic medication and with improvement in motor functions. Results: The mean standardized BADS scores showed no significant improvement in both the groups. In the de novo group, percent improvement in the standardized BADS scores showed a significant positive correlation with the LED, but not with percent improvement in UPDRS part III. In the chronic medication group, percent improvement in the standardized BADS scores was negatively correlated with change in the LED, but not with percent improvement in UPDRS part III. Multiple regression analysis using improvement in the standardized BADS score as a dependent variable and patient’s background factors (ie, age, education, disease duration, and motor and executive assessments at baseline) as independent variable showed that improvement in the executive assessment is significantly correlated with the LED only in the de novo group. Conclusion: Effects of dopaminergic drug adjustment on executive function differ according to the patient’s clinical stage and depend on LED in de novo stage. Keywords: motor disorders, dopaminergic drug, levodopa equivalent dose, correlation between executive improvement and levodopa equivalent dose, inverted U-shaped theory